Abstract | BACKGROUND: METHODS: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation ( sham), liraglutide (0.4 mg/kg/day), PYY3-36 (0.1 mg/kg/day), liraglutide+PYY3-36, and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. RESULTS: RYGB and liraglutide+PYY3-36 induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/ leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY3-36- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. CONCLUSIONS: The combination therapy of liraglutide+PYY3-36 partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.
|
Authors | Valentin Metzner, Gloria Herzog, Tobias Heckel, Thorsten Bischler, Julia Hasinger, Christoph Otto, Martin Fassnacht, Andreas Geier, Florian Seyfried, Ulrich Dischinger |
Journal | Journal of clinical medicine
(J Clin Med)
Vol. 11
Issue 3
(Jan 30 2022)
ISSN: 2077-0383 [Print] Switzerland |
PMID | 35160204
(Publication Type: Journal Article)
|